Airways Disorders Network
-
Airway clearance pharmacotherapy: Past, present, and future
The central question in non-CF bronchiectasis is no longer whether mucoactives work but for whom, under what circumstances, and at what cost in treatment burden.
-
GOLD 2026 updates in global strategy for diagnosis, management, and prevention of COPD
The GOLD 2026 report advances a contemporary model of COPD as a modifiable, biologically active disease requiring individualized and proactive management.
-
Advocating for environmental justice on behalf of pediatric patients
Pediatric pulmonologists need to advocate for policies that promote environmental justice and help ensure that all children can grow up in safe, healthy environments.
-
Airway crossroads: The overlap of bronchiectasis and obstructive lung disease
Bronchiectasis frequently coexists with asthma or COPD, forming an overlap phenotype that’s increasingly recognized but often overlooked.
-
The emerging role of biologic therapy in asthma-COPD overlap
Biologics such as dupilumab, mepolizumab, benralizumab, and tezepelumab are an emerging option for select patients with asthma-COPD overlap, particularly those with T2-high inflammatory phenotypes.
-
Advancements in pediatric airway evaluation
Pediatric airway anatomy evaluation continues to evolve with the development of newer technologies such as dynamic volumetric CT scans.
-
Strengthening more than just airways
Emerging research reveals that nutrition and exercise are two powerful yet underutilized tools in managing bronchiectasis.
-
Expanding treatments for COPD management
Recent FDA approval of dupilumab and ensifentrine marks significant progress in therapies targeting inflammation, lung function, and symptom relief for patients with COPD.
-
AI applications in pediatric pulmonary, sleep, and critical care medicine
Artificial intelligence (AI) refers to the science and engineering of making intelligent machines that mimic human cognitive functions, such as learning and problem solving.1AI tools are being increasingly utilized in pediatric pulmonary disease management to analyze the tremendous amount of patient data on environmental and physiological variables and compliance with therapy. Asthma exacerbations in young children…
-
Bronchiectasis: A call to action
Bronchiectasis is an extremely heterogeneous airways disease, making it difficult to study. For years, the noncystic fibrosis (CF) bronchiectasis community has been trying to organize to provide better care for more than half a million adults with bronchiectasis in the United States. Internationally, the Europeans created the European Bronchiectasis Registry, which has been a powerful…
